Condition: Healthy Volunteer Study · Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.
The study consists of two parts: dose escalation and expansion. It includes five cohorts in the dose-escalation phase and two expansion cohorts based on pharmacokinetic data.
This description comes directly from the study's public registry record.
Nina Shen · 02150681677 · nina.shen@arkbiosciences.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital ） | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06996704